Extract

Drug development should incorporate postmenopausal women with hypoactive sexual desire disorder (HSDD). HSDD is defined as the lack of or loss motivation to engage in sexual activity due to absent or decreased desire for at least 6 months, with accompanying distress [1]. The ICD-11 and the International Consultation on Sexual Medicine classify this as a dysfunction, whereas the International Society for the Study of Women’s Sexual Health classifies HSDD as a disorder [2]. The Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking (PRESIDE) study among others demonstrates that the largest age group of women with HSDD are those in perimenopause and menopause and yet there are no current medical treatments approved for postmenopausal women [3]. There are ~2 million women who enter menopause globally each year. If 10% of them experience HSSD per North American data suggests, at least 200 000 new patients would be eligible for treatment annually.

You do not currently have access to this article.